mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
=== 8 April === Three people were killed and eight others were injured in a Russian missile attack on Zaporizhzhia. One person was killed and five others were injured in Russian air strikes in Sumy Oblast. Two people were killed in separate attacks in Chasiv Yar and Poltava. Ukrainian hackers launched a cyberattack on a data center used by the Russian military, energy, and telecommunications industries, which affected 10,000 enterprises including Gazprom and Lukoil. The SBU arrested a former member of the Party of Regions in Sumy Oblast on suspicion of spying for Russia.
=== Other conditions === Duchenne muscular dystrophy (DMD) is an X-linked disorder caused by defective production of dystrophin. Many jurisdictions around the world have screened for, or attempted to screen for DMD using elevated levels of creatine kinase measured in dried blood spots. Because universal newborn screening for DMD has not been undertaken, affected individuals often have a significant delay in diagnosis. As treatment options for DMD become more and more effective, interest in adding a newborn screening test increases. At various times since 1978, DMD has been included (often as a pilot study on a small subset of the population) in newborn screening programs in Edinburgh, Germany, Canada, France, Wales, Cyprus, Belgium and the United States. In 2012, Belgium was the only country that continued to screen for DMD using creatine kinase levels. As treatments improve, newborn screening becomes a possibility for disorders that could benefit from early intervention, but none was previously available. Adrenoleukodystrophy (ALD), a peroxisomal disease that has a variable clinical presentation is one of the disorders that has become a target for those seeking to identify patients early. ALD can present in several different forms, some of which do not present until adulthood, making it a difficult choice for countries to add to screening programs. The most successful treatment option is a stem cell transplant, a procedure that carries a significant risk.
Cartier Women's Initiative is an annual international entrepreneurship program created in 2006 by the French luxury goods maker Cartier (jeweler). The initiative aims to drive change by empowering women impact entrepreneurs. It is open to women led and owned business from any nation and sector that demonstrate a strong, sustainable social or environmental impact.
The babies from this initial experiment were born in 1954, and the milestone was first publicized in the Cedar Rapids Gazette under the headline "Fatherhood After Death Has Now Been Proved Possible." After receiving his doctorate, Sherman accepted a position at the Biological Research Institute with the American Foundation for Biological Research in Madison, Wisconsin, in 1954. In 1957 Sherman joined the faculty at the University of Arkansas. He served as a professor there until 1992, when he became a professor emeritus and continued work until 1994. At University of Arkansas for Medical Sciences, he founded what is considered to be the second human semen cryobank. During his career, he also traveled by request to assist with the establishment of other cryobanks across the country. He also helped to establish and advocate for the Office of Minority Affairs within the School of Medical Sciences at Arkansas. From 1974 to 1975, he spent a year on sabbatical teaching at National Chung-Hsing University in Taichung, Taiwan. Throughout his career, Sherman was also active in professional societies including his role as a charter member of the Society of Cryobiology in 1964, where he also served on the society's editorial board; as a founder of the American Association of Tissue Banks, where he drafted the first standards for the cryobanking of human embryos; and as an advisor to the Food and Drug Administration on AIDS and cryobanking from 1988 to 1992.
Sources: en.wikipedia.org
== Education == Wigler graduated from Princeton University in 1970, majoring in mathematics, and in 1978 received his PhD from Columbia University in microbiology, and has spent the remainder of his career at Cold Spring Harbor Laboratory (CSHL).
=== Differential diagnosis === Pseudoacromegaly is a condition with the usual acromegaloid features but without an increase in growth hormone and IGF-1. It is frequently associated with insulin resistance. Cases have been reported due to minoxidil at an unusually high dose. It can also be caused by a selective post-receptor defect of insulin signalling, leading to the impairment of metabolic, but preservation of mitogenic, signaling.
A political battle erupted over the People's Budget, which was rejected by the House of Lords and for which the government obtained an electoral mandate at the January 1910 election. The election resulted in a hung parliament, with the government left dependent on the Irish Nationalists. Although the Lords now passed the budget, the government wished to curtail their power to block legislation. Asquith was required by King George V to fight a second general election in December 1910 (whose result was little changed from that in January) before he agreed, if necessary, to create hundreds of Liberals peers. Faced with that threat, the Lords voted to give up their veto power and allowed the passage of the Parliament Act 1911. As the price of Irish support, Asquith was now forced to introduce a third Home Rule bill in 1912. Since the House of Lords no longer had the power to block the bill, but only to delay it for two years, it was due to become law in 1914. The Unionist Ulster Volunteers, led by Sir Edward Carson, launched a campaign of opposition that included the threat of a provisional government and armed resistance in Ulster. The Ulster Protestants had the full support of the Conservatives, whose leader, Bonar Law, was of Ulster-Scots descent. Government plans to deploy troops into Ulster had to be cancelled after the threat of mass resignation of their commissions by army officers in March 1914 (see Curragh Incident). Ireland seemed to be on the brink of civil war when the First World War broke out in August 1914.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.